» Articles » PMID: 11893779

In Vivo Contribution of LCAT to Apolipoprotein B Lipoprotein Cholesteryl Esters in LDL Receptor and Apolipoprotein E Knockout Mice

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2002 Mar 15
PMID 11893779
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have indicated that LCAT may play a role in the generation of cholesteryl esters (CE) in plasma apolipoprotein B (apoB) lipoproteins. The purpose of the present study was to examine the quantitative importance of LCAT on apoB lipoprotein CE fatty acid (CEFA) composition. LCAT(-/-) mice were crossed into the LDL receptor (LDLr)(-/-) and apoE(-/-) background to retard the clearance and increase the concentration of apoB lipoprotein in plasma. Plasma free cholesterol was significantly elevated but total and esterified cholesterol concentrations were not significantly affected by removal of functioning LCAT in either the LDLr(-/-) or apoE(-/-) mice consuming a chow diet. However, when functional LCAT was removed from LDLr(-/-) mice, the CEFA ratio (saturated + monounsaturated/polyunsaturated) of plasma LDL increased 7-fold because of a 2-fold increase in saturated and monounsaturated CE, a 40% reduction in cholesteryl linoleate, and a complete absence of long chain (>18 carbon) polyunsaturated CE (20:4, 20:5n-3, and 22:6n-3), from 29.3% to 0%. Removal of functional LCAT from apoE(-/-) mice resulted in only a 1.6-fold increase in the CEFA ratio, due primarily to a complete elimination of long chain CE (7.7% to 0%). Our results demonstrate that LCAT contributes significantly to the CEFA pool of apoB lipoprotein and is the only source of plasma long chain polyunsaturated CE in these mice.

Citing Articles

HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV.

Weigand K, Peschel G, Grimm J, Muller M, Horing M, Krautbauer S Biomedicines. 2022; 10(12).

PMID: 36551908 PMC: 9775323. DOI: 10.3390/biomedicines10123152.


Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR.

Chen P, Li Y, Xiao L Exp Ther Med. 2021; 22(4):1109.

PMID: 34504563 PMC: 8383777. DOI: 10.3892/etm.2021.10543.


LXRα Regulates ChREBPα Transactivity in a Target Gene-Specific Manner through an Agonist-Modulated LBD-LID Interaction.

Fan Q, Norgaard R, Grytten I, Ness C, Lucas C, Vekterud K Cells. 2020; 9(5).

PMID: 32414201 PMC: 7290792. DOI: 10.3390/cells9051214.


Lipidome of midbody released from neural stem and progenitor cells during mammalian cortical neurogenesis.

Arai Y, Sampaio J, Wilsch-Brauninger M, Ettinger A, Haffner C, Huttner W Front Cell Neurosci. 2015; 9:325.

PMID: 26379497 PMC: 4551859. DOI: 10.3389/fncel.2015.00325.


Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion.

Marshall S, Gromovsky A, Kelley K, Davis M, Wilson M, Lee R PLoS One. 2014; 9(6):e98953.

PMID: 24901470 PMC: 4047063. DOI: 10.1371/journal.pone.0098953.